High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Despite challenges in life sciences and European automotive sectors, Dassault Systemes SE (DASTF) reports robust revenue growth and strategic advancements in AI and cloud solutions.
Moderna is likely to announce its fiscal second-quarter earnings by the end of this month, and analysts expect its losses to narrow.
The past six months have been a windfall for Moderna’s shareholders. The company’s stock price has jumped 46.4%, hitting $62.97 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
(Bloomberg) -- As worries build around the artificial intelligence trade, investors are starting to seek shelter in a more pedestrian corner of the stock market: companies with sturdy finances.Most Read from BloombergThailand Scraps Plan to End Visa-Free Entry for Indian TouristsGoogle Gemini Launch Delayed as Tech Falls Short of Internal GoalsBeckham’s IM8 Gets $1 Billion From General Catalyst for GrowthNasdaq Futures Tumble 1.5% as Chip Rout Deepens: Markets WrapUS Cyclospora Outbreak Tied to
The Morning Bull - US Market Morning Update Monday, Jul, 13 2026 US stock futures are pointing higher this morning, with E-mini S&P 500 contracts up about 0.4%, as investors digest a mix of cooling inflation and uneven growth signals abroad. Softer price data in countries like France, where inflation sits at 1.8%, suggests global cost of living pressures are easing, which can take some pressure off central banks to keep lifting interest rates. At the same time, weaker industrial output in...
Moderna shares rose nearly 20% after Science Day, driven partly by a short squeeze, while its mRNA pipeline beyond vaccines faces a multi-year path to revenue.
Stocks took an early hit on news that ChatGPT parent OpenAI might push its public offering to 2027, and a midday recovery faded into the close.
Yahoo Finance's Jared Blikre takes a closer look at some of Friday's trending tickers and stories, including Moderna (MRNA), Netflix (NFLX), and ON Semiconductor (ON).
Moderna shares were up more than 10% Friday after the biotech company revealed a new effort to make a treatment for autoimmune disorders and outlined several experimental drug projects that could help it diversify beyond Covid-19 vaccines in coming years.
June 26 (Reuters) - Futures tied to the tech-heavy Nasdaq led Wall Street losses on Friday, as chip stocks came under renewed pressure after a sharp rally in the previous session, while some megacap
Moderna shares rose 3.5% Thursday after an advisory committee voted to recommend the U.S. Food and Drug Administration approve the biotech’s proposed new flu shot for people 50 and older. The FDA had initially declined to consider Moderna’s application for the shot’s approval, but then agreed to review it after Moderna amended it. The advisory committee vote in favor of the vaccine isn’t binding, but the FDA generally follows such recommendations.
Moderna said an advisory committee voted unanimously that the benefits of the vaccine, mRNA-1010, exceed the risks for the prevention of flu in adults 50 through 64 years old, and in adults 65 and older.
Moderna (MRNA) has been struggling to shake one label for years: Covid winner. That label helped to make the company famous, but it also became a problem for the stock when pandemic demand dropped and investors questioned whether Moderna could develop a stable business beyond one historic product ...
(Updates with index/price moves, FedWatch outlook, macro data, and political/company news from the f
US equity indexes were lower on Wednesday as government bond yields rose and the Federal Reserve ann
June Nasdaq 100 E-Mini futures (NQM26) are up +0.54% this morning, signaling a rebound from yesterday’s selloff, while investors await the first Federal Reserve rate decision under Kevin Warsh.
Moderna stock surged Tuesday after documents posted ahead of a key meeting suggested the FDA would likely approve its flu shot.
It's important to consider your comfort with risk before diving in.
Parabilis stock soared on its Nasdaq debut, but a deeper dive suggests PBLS shares could extend gains further through the remainder of 2026.
The largest-ever new stock sale for a venture-backed biotech company extends a streak of large IPOs in 2026 that’s now resulted in 12 drug startups securing more than $4.1 billion combined.
Moderna (MRNA) was one of the big beneficiaries of the Covid pandemic, producing tens of billions of dollars in vaccine sales and becoming one of the most carefully watched businesses in biotechnology. Since then, the task has been to prove that the accomplishment was not a fluke. As Covid-related ...
Earnings season is winding down, but we still have a couple of big name companies reporting. This week we have Broadcom, Crowdstrike, Palo Alto Networks, Medtronic and Ciena Corp all reporting.
Roivant Sciences Ltd (ROIV) strengthens its financial position with a $2.25 billion Moderna settlement and prepares for key drug launches amidst mixed study results.
Roivant Sciences (NASDAQ:ROIV) executives used the company’s fourth-quarter earnings call to highlight new open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, upcoming pulmonary hypertension data for mosliciguat and continued preparation for a potential brepocitinib launch in d
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
